Menu
Back to Journals » Drug, Healthcare and Patient Safety » Volume 5
Diagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePath™ liquid-based pap specimens
Authors Nance K
Received 20 February 2013
Accepted for publication 21 February 2013
Published 31 March 2013 Volume 2013:5 Pages 101—104
DOI https://doi.org/10.2147/DHPS.S44258
Checked for plagiarism Yes
Keith V Nance
Department of Cytology, Rex Hospital, Raleigh, and Department of Pathology, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
Recently I communicated with the Editor regarding Drs Naryshkin and Austins’ article entitled "Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical carcinoma screening."1,2 As noted previously, this article is based on a single case report of squamous cell carcinoma of the cervix diagnosed in a patient who had abnormal Pap results but had negative Hybrid Capture 2 (HC2)(Qiagen NV, Hilden, Germany) high risk human papillomavirus (hrHPV) testing from SurePath™ (Becton-Dickinson, Franklin Lakes, NJ, USA) samples. The authors concluded that such testing should not be done using this collection medium. Interestingly, they also mentioned a 10% false negative rate for similar testing performed on FDA-approved Preservcyt® media on three of 31 invasive cervical carcinoma patients at Dr Austin’s own laboratory.
View original paper by Naryshkin and Austin
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.